Preterm labour is defined as the presence of uterine contractions of sufficient frequency and intensity to effect progressive effacement and dilatation prior to term gestation. Preterm labour and preterm births occur in approximately 12 % of all pregnancies and is the leading cause of neonatal death in the United States as well in the developing countries 1 . In addition, preterm birth accounts for 70% of neonatal morbidity, and mortality, and health care spent on the neonate 2 .
Despite the current use of material, effort and money in perinatal medical technology neonatal mortality rates continue to remain high. Implementation of effective risk identification, strategies and programms for the prevention of preterm labour may lead to successful reduction of perinatal morbidity and mortality associated with prematurity. This in turn requires both an improved understanding of the psychosocial risk factors, etiology, mechanisms of preterm labour, and programmes for accurate identification of pregnant women at risk of premature labour and delivery 3 .
Until an etiological treatment is found for preterm labour, treatment is based on preventing unwanted uterine contractions. Several therapeutic attempts have been made to inhibit uterine activity such as ethanol, prostaglandin synthetase inhibitors, magnesium sulphate, ritordine and beta-sympathomimetics. The side effects as well as the limited success have stimulated the investigators to search for new drugs such as oxytocin antagonists, calcium channel openers and calcium channel blockers 4 .
Nifedipine, a calcium channel blocking agent inhibits smooth muscle contraction by impeding the flow of calcium across the muscle cell membrane.
The aim of the study was to evaluate the tocolytic efficacy of nifedipine in preventing preterm labour and to evaluate the side effects. were cervical dilatation more than 3 cm, evidence of maternal infection, vaginal bleeding, severe PE, fetal growth restriction and oligohydramnios. Evaluation for the presence of genital infection was done by WBC count and some selected clinical parameters like uterine tenderness, maternal temperature, and foul smelling vaginal discharge. High vaginal swab was sent for routine examination and culture. Blood pressure monitoring was done regularly.
Material and Methods
Nifedipine tocolysis was started with a loading dose of 30 mg (20 mg oral and 10 mg sublingually) followed by 20 mg every 4-6 hourly depending on the uterine activity. If uterine contraction was not subsided within 12 hrs of starting the treatment the case was considered as treatment failure. Subsidence of contraction was defined by absence of subjective feelings of pain by the patient. To measure the efficacy of this drug to postpone delivery three indicators were used-delay of labour for 48 hrs, for 7 days, continuation of pregnancy till 36 weeks. Side effects like head-ache, dizziness, muscle cramps, nausea and low blood pressure were evaluated. The patients remained at bed rest for 72 hours. After tocolysis the patients were discharged from the hospital after seven days with advice to come for check-up every weekly.
Because the samples were not uniformly distributed, they were analyzed using non-parametric statistics Kreskas -Wallis U -tests. Significance was set at 0.05. Data were expressed as mean ± standard error of the mean (S.E.M). Effect of tool sets was calculated by chi-square test. Significance was set at 0.05.
Results
The characteristics of both groups are detailed in 
Discussion:
It is well documented that the efficacy of nifedipine in suppressing preterm labour appears to be as good as and possibly better than, ritrodine and terbutaline. It also appears equivalent in its ability to prolong pregnancy 5,6. One study has compared nifedipine with magnesium sulphate and ritrodine 5, 6 .They found tocolytic activity more or less same but side-effects were more in the ritrodine group. Papatsoninis et al 7 randomized 185 women in preterm labour between 20 and 33 weeks to receive either intravenous ritrodine or oral nifedipine. The authors defined preterm labour as either one contraction or more every ten minutes. The dosage regimen was 10 mg nifedipine every 15 minutes for the first hour until contraction stopped (to a maximum of 40 mg). Then a daily dose of slow release nifedipine 60-160 mg depending on the amount needed in the first hour. Significantly fewer number of women taking nifedipine delivered within 24 hours, within 48 hours and within 7 days in comparison to ritrodrine. Twelve women discontinued ritrodine because of side-effects, compared with none taking nifedipine. Fetal outcome was similar, with no difference in Apgar scores or in arterial or venous pH measurement at birth. There were significantly fewer admissions to the neonatal intensive care unit in the nifedipine group.
Kupferminc 8 undertook a randomized trial including 71 women to compare nifedipine and ritrodine, and showed a similar prolongation of pregnancy for 48 hours, 7 days and until 36 weeks. Nifedipine was administered in an initial dose of 30 mg followed by further 20 mg 90 minutes later if uterine contractions persisted. A maintenance dose of nifedipine was then given orally every 8 hours. Eleven women with twin pregnancies were included in this trial; of the six that received nifedipine three delivered after 36 weeks gestation, compared to three of the five women who received ritrodine.These results have shown comparable efficacy of nifedipine and ritrodine in suppressing preterm delivery.
Glock amd Morales 9 found nifedipine to be as effective as magnesium sulphate in delaying delivery for 48 hours, with success rate 92 % and 93 % respectively. McLaughin et al 10 showed these two drugs had similar efficacy in prolonging pregnancy and preventing birth before 37 weeks of gestation.
A major advantage noted in these studies is the reduced amount of maternal side effects reported with the use of nifedipine than with ritrodine or terbutaline.A systematic review in the Cochrane Library, 11 comparing nifedipine and the beta-sympathmimetic drugs showed that nifedipine reduces the number of deliveries of newborn infants weighing less than 2500gm, but the number of infants admitted to the neonatal intensive care unit was increased. There was no difference in the stillbirth or neonatal death rate.
The tocolytic efficacy of nifedipine in the present study is 82%, which is statistically significant and is comparable with ritrodine, terbutaline or magnesium sulphate as shown in other studies [7] [8] [9] . Since some of the drugs like terbutaline are not available and facilities for ICU support are needed for terbutaline and ritrodine, so alternatively nifidepine can be recommended as a tocolytic agent as it has fewer side effects. The dosage used in the present study was similar to the dose used in Kupfermins et al 8 . It was seen that successful tocolysis can be achieved with the given dosage.
The concern for side-effects is an important factor for the choice of some of the tocolytic drugs like betamimetic. The various side effects in ritordine treated group were tremor, palpitation, and nervousness and less important headache and chest pain or dizziness 9 .
In the present study side effects of nifedipine were less frequent and severe flushes and headache being the most discomforting problem. Similar side effects for nifedipine were also reported by other authors 12 .
The present study provides data supporting nifedipine as a safe tocolytic agent, better tolerated and with less maternal side-effects. Though the series is small but still multicenter trial can be done for evaluating the tocolytic efficacy of nifedipne.
